Quantcast Acelity - KCI, an Acelity Company, Shares Data Supporting Improved Patient Compliance and Wound Healing Outcomes with iOn PROGRESS™ Remote Therapy Monitoring

KCI, an Acelity Company, Shares Data Supporting Improved Patient Compliance and Wound Healing Outcomes with iOn PROGRESS™ Remote Therapy Monitoring

April 30, 2018 | San Antonio
  • Data Presented at Symposium of Advanced Wound Care (SAWC) Spring Builds Upon Study Results Recently Published in WOUNDS, and Underscores KCI’s Unsurpassed Leadership in Digital Health
  • Company Creates a new Digital Wound Care Franchise, to Commercialize Major Advancements in Wound Care Leveraging Technology and Data to Improve Outcomes
KCI, an Acelity Company, presented study results that demonstrate increased patient therapy usage immediately after patient contact using iOn PROGRESS™ Remote Therapy Monitoring. The oral presentation, presented at the 2018 Symposium of Advanced Wound Care (SAWC) Spring Conference explained that the day following an adherence call, 73.5 percent of patients increased therapy use, with an average increase of 8 hours. Additionally, as adherence increased, the rate of daily change in wound volume reduction also increased.
“These results are powerful because we now have evidence that proves we can and do change patient behavior, dramatically improving compliance using our connectivity offering,” said Ron Silverman, M.D., Chief Medical Officer, KCI. “Patient adherence to treatment is an ever-present concern for clinicians, and we have successfully harnessed technology to alleviate that concern for more effective home care, and to provide smarter solutions for our customers and their patients.”
The presentation titled “A patient centered remote therapy monitoring program focusing on increased adherence to wound therapy: a large cohort study,” is an extension of a recently published study in WOUNDS by Leah Griffin, MS, and Laura M Leyva Casillas, MBA, MSBA. The presentation addressed the challenge of low patient compliance with negative pressure wound therapy (NPWT) therapy by analyzing iOn PROGRESS™ Remote Therapy Monitoring and the ability to drive adherence through active engagement when there is a decrease in therapy usage. In addition to an increase in adherence, patients rate of daily change in wound volume reduction increased from 1.42 percent change in volume reduction per day for patients with less than 60 percent therapy use to 2.23 percent change for patients with 90 to 100 percent therapy use.
KCI is propelling advanced wound care into the digital age with solutions that enable patient intervention and enhance the provider experience. In order to continue building upon these advancements, KCI formally announces a dedicated Digital Wound Care Franchise. Led by Vikram S. Bajaj, Digital Wound Care Franchise Leader and Senior Vice President, Strategy and Business Development, the franchise’s purpose is to drive digital innovation and leverage all the benefits that technology and data capture can provide to patients, clinicians and payers.
“KCI disrupted the market in the treatment of chronic and acute wounds in 1995 with the introduction of V.A.C.® Therapy, and has since grown to become the largest wound care company in the world,” said R. Andrew Eckert, President and CEO of KCI. “Unmatched by our competition, we still carry that same pioneering spirit as we bring the digital health revolution to wound care, so that we can continue our legacy of improving the way wounds are treated.”
“The value our digital health solutions provide to patients, clinicians and healthcare systems is unique, and this cluster of data supporting what we’ve established validates that our technology improves outcomes,” said Bajaj. “We intend to focus our innovation on solutions that will succeed in the changing market and reduce costs to value-based healthcare systems.”
KCI presented more than 25 abstracts and two oral presentations at the SAWC Spring conference, showcasing substantial clinical evidence supporting a full range of wound management products. Together, this bolus of evidence underscores the unsurpassed clinical and economic value of the Acelity portfolio of wound care solutions.
About iOn PROGRESS™ Remote Therapy Monitoring
iOn PROGRESS™ Remote Therapy Monitoring is the first system to deliver continuous at-home monitoring for patients prescribed NPWT in the home. It works in conjunction with the ACTIV.A.C.™ System to monitor adherence and securely transmit data to the KCI iOn PROGRESS™ Care Network, a group of highly-trained individuals who interact with patients to drive proper utilization.
About KCI, an Acelity Company
KCI, an Acelity Company, the most trusted brand in advanced wound care, is committed to developing innovative healing solutions for customers and patients across the care continuum. Our unsurpassed product portfolio is available in more than 90 countries and delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Committed to advancing the science of healing, KCI sets the standard for leading advanced wound therapy innovation. Headquartered in San Antonio, Texas, KCI employs nearly 5,000 people around the world.

For more information, contact:

Kathryn Skeen
Corporate Communications
Phone: +1 210-882-2067
Email: kathryn.skeen@acelity.com
Jathan Tucker
Investor Relations
Phone: +1 210-255-6816
Email: jathan.tucker@acelity.com

Footer Navigation